Aprott / istock via getty images
Food and Drug Administration (FDA) has also widened the American indications of the therapy of popular weight loss of Novo Nordisk (NVO), which allows its use against ster -pole (Mash) associated with metabolic dysfunction.
Approval marks the entry of the market of
